Compare FMC Corp (FMC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs GSK plc — how do they compare? FMC Corp trades at $8.95 (market cap $1.39B), while GSK plc trades at $46.82 (market cap $91.88B). The key difference: GSK plc is far larger — about 66.1× FMC Corp's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and GSK plc for 93 Days on average.
| FMC | GSK | |
|---|---|---|
Market Cap | $1.39B | $91.88B |
Volume | 4,145,979 | 7,730,529 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $61.18 |
52-Week Low | $8.44 | $43.24 |
Typical Hold Time | 68 Days | 93 Days |
Enterprise Value | $5.19B | $111.88B |
Dividend Yield | 3.59% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $9.09, up 0.66% with bearish technical signals despite recent earnings beats. The agricultural sciences company faces severe profitability challenges with a -84.83% net margin and negative ROE, though valuation ratios appear attractive with P/S of 0.35 and P/B of 0.86. Recent developments include regulatory filings for new herbicides in Brazil and a minority equity investment from Tessenderlo Group.
While analyst consensus suggests moderate upside to the $14.60 price target, significant operational challenges and negative cash flow from operations in 2025 present substantial risks. The company's aggressive deleveraging efforts and new product pipeline offer potential catalysts, but investors face headwinds from cyclical industry pressures and persistent profitability issues.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
